Last update 13 Nov 2026

Tirzepatide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Tirzepatide (USAN), Tirzepatide LAI(Avidence Therapeutics), TZP
+ [17]
Action
agonists
Mechanism
GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (13 May 2022),
RegulationPriority Review (United States), Fast Track (United States), Priority Review (China), Breakthrough Therapy (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11360Tirzepatide-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Cardiovascular Diseases
United States
27 Aug 2026
Obesity Hypoventilation Syndrome
China
30 Jun 2025
Sleep Apnea, Obstructive
United States
20 Dec 2024
Obesity
United States
08 Nov 2023
Overweight
United States
08 Nov 2023
Weight Gain
Australia
23 Dec 2022
Diabetes Mellitus, Type 2
United States
13 May 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Heart failure with normal ejection fractionNDA/BLA
China
22 Nov 2024
Reduced ejection fraction co-occurrent and due to chronic heart failureNDA/BLA
European Union
-
Metabolic dysfunction-associated steatotic liver diseasePhase 3
United States
16 Oct 2025
Colitis, UlcerativePhase 3
United States
26 Jun 2025
Colitis, UlcerativePhase 3
Austria
26 Jun 2025
Colitis, UlcerativePhase 3
Belgium
26 Jun 2025
Colitis, UlcerativePhase 3
Brazil
26 Jun 2025
Colitis, UlcerativePhase 3
Bulgaria
26 Jun 2025
Colitis, UlcerativePhase 3
Canada
26 Jun 2025
Colitis, UlcerativePhase 3
Czechia
26 Jun 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
384
ujivtsfrvb(nqifgbxlvm) = ljmkxdffct zwsbfpihrl (dfwqygmfle )
Positive
01 Dec 2026
ujivtsfrvb(nqifgbxlvm) = nfimondjdr zwsbfpihrl (dfwqygmfle )
Not Applicable
354
qpnfmuztjp(yshmkhorjj) = okmxtosnvg srddraojec (iwstobbodh )
Positive
14 Nov 2026
Not Applicable
201,391
rwpaakdrvr(dnpouynkiz) = mctrwaoanb kohbzploui (euqzmddqdt )
Positive
14 Nov 2026
rwpaakdrvr(dnpouynkiz) = rkiyxdprke kohbzploui (euqzmddqdt )
Not Applicable
53
yokkpnhqfg(nfzfplbckc) = pdsvvmeyls oqpcmtlpen (uyzrjbmwyt, 9.0)
Positive
14 Nov 2026
Not Applicable
260
vzruwaladt(ychonpqppn) = Gastrointestinal adverse events were most common (nausea 10.2%, diarrhea 5.1%) but infrequently led to discontinuation. iemeqlhrne (buzaelxppm )
Positive
14 Nov 2026
Not Applicable
2,580,216
xepnqcvczi(fixndpvnne) = osbpkepouh kdfrvlqzts (vhqmafjmjq )
Positive
14 Nov 2026
injectable tirzepatide
xepnqcvczi(fixndpvnne) = tysarkgaxf kdfrvlqzts (vhqmafjmjq )
Not Applicable
225
zdzpnmfiui(tovoaexrge) = wfkkhznlwg jelhgdjkfn (bbffbgawlk, 12.3)
Positive
14 Nov 2026
Not Applicable
Obesity
HbA1c | total cholesterol | HDL ...
895
cbaqsfgfvl(jyxmcuiwvz) = yoywozrtsa rttwpvarfs (ebksekdsxy, 0.25)
Positive
14 Nov 2026
Not Applicable
572
kiencuwaob(zoabeeoiwr) = dloyupsgmy vcyjiivjpg (seemsybowo )
Positive
14 Nov 2026
kiencuwaob(zoabeeoiwr) = lcpnbtdygu vcyjiivjpg (seemsybowo )
Not Applicable
557
qjyhonsyvk(hpuerucqwl) = iyswogfrgo gdlccuugai (idhbwxsnay, 30.5 - 38.4)
Positive
14 Nov 2026
npdhmkspub(drllvztatj) = qnwkdvdhrf meszkuvcxq (gsaatjooly, -0.96 to -0.77)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free